A PHASE II PILOT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS AND PHARMACOKINETICS OF IDES IN ASYMPTOMATIC ANTIBODY-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) PATIENTS WITH LOW ADAMTS13 ACTIVITY

Trial Profile

A PHASE II PILOT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS AND PHARMACOKINETICS OF IDES IN ASYMPTOMATIC ANTIBODY-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) PATIENTS WITH LOW ADAMTS13 ACTIVITY

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs IdeS (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Adverse reactions; Proof of concept
  • Sponsors Hansa Medical AB
  • Most Recent Events

    • 21 Dec 2016 According to a Hansa Medical AB media release, the company has decided to terminate this trial dur to non-favourable risk benefit profile observed after review of initial results from the trial.
    • 21 Dec 2016 According to a Hansa Medical AB media release, status changed from recruiting to discontinued.
    • 11 Oct 2016 According to a Hansa Medical AB media release, this trial expected to be completed during 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top